Spots Global Cancer Trial Database for Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

Official Title: Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

Study ID: NCT05136807

Conditions

Monoclonal Gammopathy of Undetermined Significance

Smoldering Plasma Cell Myeloma

Interventions

Quality-of-Life Assessment

Questionnaire Administration

Study Description

Brief Summary: This study examines the quality of life in patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma. Collecting quality of life information from patients may help doctors learn more about the most common symptoms and concerns patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma may have.

Detailed Description: PRIMARY OBJECTIVE: I. Describe baseline and follow up quality of life and monoclonal gammopathy of unknown significance/smoldering multiple myeloma (MGUS/SMM) related anxiety of patients with MGUS/SMM already participating in clinical trials at MD Anderson Cancer Center. SECONDARY OBJECTIVE: I. Identify the most common symptoms/patients concerns to evaluate future interventions for treatment/prevention in this population. OUTLINE: Patients complete quality of life questionnaires over 10-15 minutes at baseline and every 6 months for patients participating in an observational study or every month for patients participating in a treatment study for up to 3 years.